| Literature DB >> 30042683 |
Jin-Hua Tao1, Jin-Ao Duan2, Wei Zhang1, Shu Jiang2, Jian-Ming Guo2, Dan-Dan Wei2.
Abstract
Studies have indicated that Chrysanthemum polysaccharides (CP) could prominently ameliorate colitis rats, but its possible mechanism remains unclear. In this study, the underlying mechanism of CP was explored by the metabolic profiling analysis and correlated signaling pathways. TNBS/ethanol induced colitis was used to investigate the intervention efficacy following oral administration of CP. The levels of cytokines such as TNF-α, IL-6, IFN-γ and IL-1β, and the activities of SOD, MPO, and MDA were determined. We also performed western-blot for p65, TLR4, p-JAK2, and STAT3 protein expression in the colon tissue to probe their mechanisms of correlated signaling pathways. What's more, the metabolic changes in plasma and urine from colitis rats were investigated based on UPLC-Q-TOF/MS combined with MetabolynxTM software. The potential biomarkers and metabolic pathways were also tentatively confirmed. The metabolic profiles of plasma and urine were clearly improved in model rats after oral administration of CP. Thirty-two (17 in serum and 15 in urine) potential biomarkers were identified. The endogenous metabolites were mainly involved in linoleic acid, retinol, arachidonic acid, glycerophospholipid and primary bile acid metabolism in plasma, and nicotinate and nicotinamide, ascorbate and aldarate, histidine and β-alanine metabolism in urine. After polysaccharides intervention, these markers turned back to normal level at some extent. Meanwhile, the elevated expression levels of pp65, TLR4, p-STAT3, and p-JAK2 were significantly decreased after treatment. Results suggested that CP would be a potential prebiotics for alleviation of TNBS-induced colitis. The study paved the way for the further exploration of the pathogenesis, early diagnosis and curative drug development of the colitis.Entities:
Keywords: Chrysanthemum polysaccharides; IBD; colitis; metabonomics; signaling pathway
Year: 2018 PMID: 30042683 PMCID: PMC6049019 DOI: 10.3389/fphar.2018.00746
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
The identified and change trend of the potential biomarkers between colitis and normal rats.
| Number | tR/min | Actual-mass | Formula | Ion mode | Metabolite | Trend | VIP | KEGG | HMDB | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3.21 | 246.0921 | C5H12O7P2 | - | Dimethylallylpyrophosphate | ↓ | 2.25 | C00235 | HMDB01120 | Urine |
| 2 | 4.21 | 108.0948 | C6H4O2 | - | 1,2-Benzoquinone | ↑ | 1.95 | C02351 | HMDB12133 | Urine |
| 3 | 3.82 | 114.1026 | C4H6N2O2 | - | Dihydrouracil | ↓ | 1.02 | C00429 | HMDB00076 | Urine |
| 4 | 4.45 | 176.1241 | C6H8O6 | - | ↑ | 1.53 | C02670 | HMDB06355 | Urine | |
| 5 | 6.04 | 122.1246 | C6H6N2O | - | Niacinamide | ↓ | 1.25 | C00153 | HMDB01406 | Urine |
| 6 | 3.71 | 257.2213 | C8H20NO6P | - | Glycerophosphocholine | ↓ | 1.34 | C00670 | HMDB00086 | Urine |
| 7 | 3.17 | 161.1558 | C6H11NO4 | - | Aminoadipic acid | ↓ | 2.03 | C00956 | HMDB00510 | Urine |
| 8 | 3.15 | 194.1394 | C6H10O7 | - | ↓ | 2.04 | C00191 | HMDB00127 | Urine | |
| 9 | 14.7 | 140.1399 | C6H8N2O2 | + | Methylimidazoleacetic acid | ↑ | 1.93 | C05828 | HMDB02820 | Urine |
| 10 | 12.81 | 138.124 | C6H6N2O2 | + | Urocanic acid | ↓ | 1.64 | C00785 | HMDB00301 | Urine |
| 11 | 14.65 | 148.18 | C5H8O3S | + | 2-Oxo-4-methylthiobutanoic acid | ↑ | 3.35 | C01180 | HMDB01553 | Urine |
| 12 | 3.17 | 337.2198 | C11H16NO9P | + | Nicotinic acid mononucleotide | ↓ | 2.64 | C01185 | HMDB01132 | Urine |
| 13 | 3.7 | 339.1959 | C9H14N3O9P | + | 5-amino-1-(5-phospho- | ↓ | 2.52 | C04751 | HMDB06273 | Urine |
| 14 | 12.81 | 184.1507 | C5H15NO4P | + | Phosphorylcholine | ↓ | 1.63 | C00588 | HMDB01565 | Urine |
| 15 | 4.54 | 129.157 | C6H11NO2 | + | ↓ | 1.70 | C00408 | HMDB00716 | Urine | |
| 16 | 11.27 | 280.4455 | C18H32O2 | - | Linoleic acid | ↓ | 7.73 | C01595 | HMDB00673 | Plasma |
| 17 | 10.73 | 284.4357 | C20H28O | - | Retinal | ↓ | 4.11 | C00376 | HMDB01358 | Plasma |
| 18 | 11.01 | 304.4669 | C20H32O2 | - | Arachidonic acid | ↓ | 5.77 | C00219 | HMDB01043 | Plasma |
| 19 | 10.04 | 302.451 | C20H30O2 | - | Retinyl ester | ↓ | 3.05 | C02075 | HMDB03598 | Plasma |
| 20 | 7.54 | 481.309 | C26H45NO6S | - | Taurochenodesoxycholic acid | ↓ | 3.43 | C05465 | HMDB00951 | Plasma |
| 21 | 14.71 | 182.08 | C4H9NO2Se | - | Se-Methylselenocysteine | ↑ | 1.24 | C05689 | HMDB04113 | Plasma |
| 22 | 3.68 | 408.5714 | C24H40O5 | - | Cholic acid | ↓ | 1.96 | C00695 | HMDB00619 | Plasma |
| 23 | 3.9 | 465.6227 | C26H43NO6 | - | Glycocholic acid | ↑ | 1.43 | C01921 | HMDB00138 | Plasma |
| 24 | 7.05 | 318.4504 | C20H30O3 | - | Leukotriene A4 | ↑ | 2.08 | C00909 | HMDB01337 | Plasma |
| 25 | 5.95 | 392.572 | C24H40O4 | - | Chenodeoxycholic acid | ↓ | 1.98 | C02528 | HMDB00518 | Plasma |
| 26 | 14.45 | 466.717 | C27H46O4S | - | Cholesterol sulfate | ↑ | 1.10 | C18043 | HMDB00653 | Plasma |
| 27 | 10.31 | 523.6832 | C26H54NO7P | - | LysoPC (18:0) | ↓ | 1.07 | C04230 | HMDB10384 | Plasma |
| 28 | 4.58 | 449.6233 | C26H43NO5 | - | Chenodeoxycholic acid glycine conjugate | ↓ | 1.02 | C05466 | HMDB00637 | Plasma |
| 29 | 9.75 | 165.1461 | C8H7NO3 | - | Formylanthranilic acid | ↓ | 1.01 | C05653 | HMDB04089 | Plasma |
| 30 | 7.89 | 183.2044 | C9H13NO3 | + | Normetanephrine | ↑ | 1.09 | C05589 | HMDB00819 | Plasma |
| 31 | 1.71 | 187.1947 | C11H9NO2 | + | Indoleacrylic acid | ↓ | 1.73 | C00331 | HMDB00734 | Plasma |
| 32 | 8.29 | 329.5179 | C19H39NO3 | + | Dihydroceramide | ↑ | 1.06 | C12126 | HMDB06752 | Plasma |